Chongqing Pharscin Pharmaceutical Co., Ltd.'s (SZSE:002907) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall StMar 21 18:51 ET

Huasen Pharmaceutical Gets Approval for Re-Registration for Six Drugs

MT NewswiresMar 14 03:00 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Chongqing Pharscin Pharmaceutical (002907.SZ): The company has not yet integrated with deepseek.

Gelonghui, February 18th丨Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investor interaction platform that the company has not yet connected to deepseek.

Gelonghui FinanceFeb 18 02:18 ET

Chongqing Pharscin Pharmaceutical Receives Re-Registration Approval for Orlistat Capsules

MT NewswiresFeb 18 02:00 ET

Chongqing Pharscin Pharmaceutical (002907.SZ): Chengdu Dijing has completed a Shareholding reduction of 3.00%.

On February 10, Gelonghui reported that Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company recently received a notification from Chengdu Dijiang regarding the completion of the shareholding reduction plan. As of now, the Chengdu Dijiang shareholding reduction plan has been completed, with a total reduction of 12.527825 million shares, accounting for a reduction ratio of 3.00%.

Gelonghui FinanceFeb 10 05:02 ET